Immunovant (IMVT) News Today $13.86 -1.37 (-8.97%) Closing price 03:59 PM EasternExtended Trading$14.01 +0.16 (+1.15%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Baker BROS. Advisors LPBaker BROS. Advisors LP boosted its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 39.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,707,881 shares of the company's stock after acquiring an aMay 6 at 7:39 AM | marketbeat.comBoxer Capital Management LLC Makes New $20.44 Million Investment in Immunovant, Inc. (NASDAQ:IMVT)Boxer Capital Management LLC bought a new position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 825,000 shares of the company's stock, valued at approximately $20,435,000. IMay 4 at 6:25 AM | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Sold by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD reduced its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 24.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 916,250 shares of the company's stockMay 4 at 4:10 AM | marketbeat.comAquatic Capital Management LLC Takes Position in Immunovant, Inc. (NASDAQ:IMVT)Aquatic Capital Management LLC acquired a new position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 47,648 shares of the company's stock, valueMay 2, 2025 | marketbeat.comEmerald Mutual Fund Advisers Trust Decreases Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)Emerald Mutual Fund Advisers Trust lowered its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 156,097 shares of the company's stock after seMay 1, 2025 | marketbeat.comThyroid Eye Disease Treatment Market Size (7MM) was ~USD 1,993 Million in 2022 and is projected to increase by 2034, estimates DelveInsightApril 30, 2025 | theglobeandmail.comImmunovant (NASDAQ:IMVT) Shares Up 3.4% - Time to Buy?Immunovant (NASDAQ:IMVT) Stock Price Up 3.4% - What's Next?April 30, 2025 | marketbeat.comRenaissance Technologies LLC Sells 108,100 Shares of Immunovant, Inc. (NASDAQ:IMVT)Renaissance Technologies LLC lessened its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 57.2% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 80,900 shares of the company's stock after selling 108,100 shares during the period. RenaissancApril 28, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Bought by Two Seas Capital LPTwo Seas Capital LP grew its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 123.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,511,614 shares of the company's stock after purchasing an additApril 27, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Increases Stock Position in Immunovant, Inc. (NASDAQ:IMVT)T. Rowe Price Investment Management Inc. lifted its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 53.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 5,117,234 shares of the company's stock after acquiring an additional 1,786,217April 27, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) CTO Jay S. Stout Sells 1,925 SharesApril 26, 2025 | insidertrades.comCanada Pension Plan Investment Board Increases Position in Immunovant, Inc. (NASDAQ:IMVT)Canada Pension Plan Investment Board increased its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 7,833.3% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 95,200 shares of the company's stock after buying an additional 94,000 shares during the qApril 26, 2025 | marketbeat.comBrokerages Set Immunovant, Inc. (NASDAQ:IMVT) PT at $38.33April 26, 2025 | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from BrokeragesImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten ratings firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and oneApril 25, 2025 | marketbeat.comImmunovant's (IMVT) "Neutral" Rating Reiterated at UBS GroupUBS Group reiterated a "neutral" rating and issued a $17.00 target price (down from $38.00) on shares of Immunovant in a report on Tuesday.April 24, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) is Alpine Global Management LLC's 2nd Largest PositionAlpine Global Management LLC boosted its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 14.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,158,904 shares of the company's stock after buyApril 24, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Shares Gap Down - Here's WhyImmunovant (NASDAQ:IMVT) Shares Gap Down - Here's WhyApril 23, 2025 | marketbeat.comImmunovant downgraded to Neutral from Buy at UBSApril 23, 2025 | markets.businessinsider.comUBS Downgrades Immunovant (IMVT)April 23, 2025 | msn.comImmunovant, Inc. (NASDAQ:IMVT) Shares Sold by Rock Springs Capital Management LPRock Springs Capital Management LP decreased its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 25.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 909,103 shares of the company's stockApril 23, 2025 | marketbeat.comInvesco Ltd. Has $12.49 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT)Invesco Ltd. decreased its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 15.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 504,032 shares of the company's stock after selling 90,210 sharesApril 23, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Short Interest UpdateImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 19,690,000 shares, an increase of 24.6% from the March 15th total of 15,800,000 shares. Currently, 28.9% of the company's stock are sold short. Based on an average daily trading volume, of 1,700,000 shares, the short-interest ratio is currently 11.6 days.April 22, 2025 | marketbeat.com22,740 Shares in Immunovant, Inc. (NASDAQ:IMVT) Acquired by XTX Topco LtdXTX Topco Ltd acquired a new stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 22,740 shares of the company's stock, valued at approximately $563,000. Other hedge funds and otherApril 22, 2025 | marketbeat.comImmunovant appoints Eric Venker as CEO, Girao as CFOApril 22, 2025 | markets.businessinsider.comImmunovant, Inc. (NASDAQ:IMVT) Holdings Raised by Jump Financial LLCJump Financial LLC increased its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 111.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 129,668 shares of the company's stock after purchasing an aApril 20, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) CFO Sells $44,565.77 in StockApril 18, 2025 | insidertrades.comAffinity Asset Advisors LLC Sells 203,000 Shares of Immunovant, Inc. (NASDAQ:IMVT)Affinity Asset Advisors LLC reduced its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 67.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 100,000 shares of the company's stock after selling 203,000 shares durinApril 17, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Sold by Russell Investments Group Ltd.Russell Investments Group Ltd. lessened its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 11.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 222,806 shares of the company's stock after selling 28,686 shaApril 16, 2025 | marketbeat.com20,573 Shares in Immunovant, Inc. (NASDAQ:IMVT) Purchased by F M Investments LLCF M Investments LLC bought a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 20,573 shares of the company's stock, valued at approximately $510,000. Several other laApril 14, 2025 | marketbeat.com29,233 Shares in Immunovant, Inc. (NASDAQ:IMVT) Purchased by ExodusPoint Capital Management LPExodusPoint Capital Management LP acquired a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 29,233 shares of the company's stock, valued at approxApril 14, 2025 | marketbeat.comFmr LLC Increases Stock Position in Immunovant, Inc. (NASDAQ:IMVT)Fmr LLC grew its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 4.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 13,097,915 shares of the company's stock after purchasing an additional 560,344 shares during the qApril 13, 2025 | marketbeat.comInsider Selling: Immunovant, Inc. (NASDAQ:IMVT) CEO Sells 28,094 Shares of StockApril 12, 2025 | insidertrades.comImmunovant (NASDAQ:IMVT) Shares Gap Down - Should You Sell?Immunovant (NASDAQ:IMVT) Shares Gap Down - Here's What HappenedApril 11, 2025 | marketbeat.comJPMorgan Chase & Co. Has $28.57 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT)JPMorgan Chase & Co. boosted its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 405.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,153,338 shares of the company's stock afApril 10, 2025 | marketbeat.comIs Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?April 9, 2025 | finance.yahoo.comImmunovant (NASDAQ:IMVT) Sets New 12-Month Low - What's Next?Immunovant (NASDAQ:IMVT) Reaches New 1-Year Low - Here's What HappenedApril 9, 2025 | marketbeat.comADAR1 Capital Management LLC Sells 354,429 Shares of Immunovant, Inc. (NASDAQ:IMVT)ADAR1 Capital Management LLC reduced its stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 31.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 787,478 shares of the comApril 9, 2025 | marketbeat.comNorges Bank Purchases Shares of 637,947 Immunovant, Inc. (NASDAQ:IMVT)Norges Bank acquired a new position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 637,947 shares of the company's stock, valued at approximatelyApril 9, 2025 | marketbeat.comRaymond James Financial Inc. Makes New $505,000 Investment in Immunovant, Inc. (NASDAQ:IMVT)Raymond James Financial Inc. purchased a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 20,382 shares of the company's stock, valued at approximately $505April 9, 2025 | marketbeat.comIs Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?April 8, 2025 | msn.comFranklin Resources Inc. Lowers Holdings in Immunovant, Inc. (NASDAQ:IMVT)Franklin Resources Inc. lowered its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 6.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 984,063 shares of the company's stock after selliApril 8, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. grew its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 0.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,679,414 shares of the company's stock after purchasing an additional 20,614 shares duApril 8, 2025 | marketbeat.comRhenman & Partners Asset Management AB Sells 98,000 Shares of Immunovant, Inc. (NASDAQ:IMVT)Rhenman & Partners Asset Management AB decreased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 40.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 145,000 shares of the company's stock after selling 98,000 shares during the periApril 7, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Sees Large Volume Increase - Still a Buy?Immunovant (NASDAQ:IMVT) Sees Strong Trading Volume - Here's WhyApril 4, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Trading Down 5.3% - Time to Sell?Immunovant (NASDAQ:IMVT) Trading Down 5.3% - Time to Sell?April 3, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Sets New 12-Month Low - Here's What HappenedImmunovant (NASDAQ:IMVT) Hits New 12-Month Low - What's Next?April 1, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Sold by Pictet Asset Management Holding SAPictet Asset Management Holding SA trimmed its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 4.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,175,685 shares of the company's stock after selling 54,624 shares during tApril 1, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Receives Average Rating of "Buy" from BrokeragesShares of Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) have been given a consensus recommendation of "Buy" by the ten analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and oneMarch 30, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Trading 5.3% Higher - Here's WhyImmunovant (NASDAQ:IMVT) Shares Up 5.3% - Time to Buy?March 28, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Shares Down 3.5% - Time to Sell?Immunovant (NASDAQ:IMVT) Shares Down 3.5% - Here's WhyMarch 26, 2025 | marketbeat.com Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Media Mentions By Week IMVT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMVT News Sentiment▼1.500.69▲Average Medical News Sentiment IMVT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMVT Articles This Week▼76▲IMVT Articles Average Week Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VTRS News Today QGEN News Today ROIV News Today RVMD News Today LNTH News Today BBIO News Today BPMC News Today TLX News Today SRPT News Today LEGN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMVT) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMVT Stock Free IMVT Stock Alerts